trending Market Intelligence /marketintelligence/en/news-insights/trending/ekeW57tF-KUsu9124-ic9Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CTD Holdings raises $2M to develop rare genetic disorder drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

CTD Holdings raises $2M to develop rare genetic disorder drug

CTD Holdings Inc. closed a private placement of 3.1 million units to raise $2 million in gross proceeds.

The units were priced at 65 cents each and were made up of a common share and a warrant to buy additional stock of the company, also for 65 cents.

The company will use the proceeds to fund the development of its lead drug candidate Trappsol. Trappsol is being evaluated for the treatment of Niemann-Pick disease type C, a rare genetic disease that causes fatal neurologic, liver, lung and other organ dysfunction.

Alachua, Fla.-based CTD Holdings plans to present initial safety and efficacy data with regulators in early 2019.